Items where Author is "Etemadifar, M."

Up a level
Export as [feed] Atom [feed] RSS 1.0 [feed] RSS 2.0
Group by: Item Type | No Grouping
Number of items: 4.

Sedaghat, N. and Motedayyen, H. and Alsahebfosoul, F. and Etemadifar, M. and Ostadi, V. and Kianpour, F. and Akbari, M. and Vestri, E. and Zarkesh Esfahani, S.H. (2019) Increased expression of lymphocyte activation gene-3 by regulatory t cells in multiple sclerosis patients with fingolimod treatment Multiple sikleroz hastalarında fingolimod tedavisi sonucu düzenleyici t hücrelerinde lenfosit aktivasyon gen-3 ekspresyonunda artı�. Turkish Journal of Immunology, 7 (1). pp. 31-39.

Etemadifar, M. and Jahanbani-Ardakani, H. and Farrokhi, M. and Fereidan-Esfahani, M. and Changaei, H. and Aghadoost, N. and Ardakani, A.J. and Moradkhani, N. (2017) Cancer risk among patients with multiple sclerosis: A cohort study in Isfahan, Iran. Caspian Journal of Internal Medicine, 8 (3). pp. 172-177.

Farrokhi, M. and Amani-Beni, A. and Etemadifar, M. and Rezaei, A. and Rivard, L. and Rafiee-Zadeh, A. and Sedaghat, N. and Ghadimi, M. (2015) Effect of fingolimod on platelet count among multiple sclerosis patients. International Journal of Preventive Medicine, 2015 (DECEMB).

Farrokhi, M. and Rezaei, A. and Amani-Beni, A. and Etemadifar, M. and Kouchaki, E. and Zahedi, A. (2015) Increased serum level of IL-37 in patients with multiple sclerosis and neuromyelitis optica. Acta Neurologica Belgica, 115 (4). pp. 609-614.

This list was generated on Wed Oct 28 00:45:39 2020 EDT.